These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31494254)

  • 1. Probiotics for intestinal decolonization of ESBL-producing Enterobacteriaceae: a randomized, placebo-controlled clinical trial.
    Ljungquist O; Kampmann C; Resman F; Riesbeck K; Tham J
    Clin Microbiol Infect; 2020 Apr; 26(4):456-462. PubMed ID: 31494254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decolonization of intestinal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae with oral colistin and neomycin: a randomized, double-blind, placebo-controlled trial.
    Huttner B; Haustein T; Uçkay I; Renzi G; Stewardson A; Schaerrer D; Agostinho A; Andremont A; Schrenzel J; Pittet D; Harbarth S
    J Antimicrob Chemother; 2013 Oct; 68(10):2375-82. PubMed ID: 23719234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal decolonization of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBL): a retrospective observational study in patients at risk for infection and a brief review of the literature.
    Rieg S; Küpper MF; de With K; Serr A; Bohnert JA; Kern WV
    BMC Infect Dis; 2015 Oct; 15():475. PubMed ID: 26511929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year prospective evaluation of colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae: time course and risk factors.
    Papst L; Beović B; Seme K; Pirš M
    Infect Dis (Lond); 2015 Sep; 47(9):618-24. PubMed ID: 25865350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multinational study of colonization with extended spectrum β-lactamase-producing Enterobacteriaceae in healthcare personnel and family members of carrier patients hospitalized in rehabilitation centres.
    Adler A; Baraniak A; Izdebski R; Fiett J; Salvia A; Samso JV; Lawrence C; Solomon J; Paul M; Lerman Y; Schwartzberg Y; Mordechai E; Rossini A; Fierro J; Lammens C; Malhotra-Kumar S; Goossens H; Hryniewicz W; Brun-Buisson C; Gniadkowski M; Carmeli Y;
    Clin Microbiol Infect; 2014 Aug; 20(8):O516-23. PubMed ID: 24450778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High carriage rate of extended-spectrum beta-lactamase-producing Enterobacteriaceae among patients admitted for surgery in Tanzanian hospitals with a low rate of endogenous surgical site infections.
    Moremi N; Claus H; Rutta L; Frosch M; Vogel U; Mshana SE
    J Hosp Infect; 2018 Sep; 100(1):47-53. PubMed ID: 29852267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history and decolonization strategies for ESBL/carbapenem-resistant Enterobacteriaceae carriage: systematic review and meta-analysis.
    Bar-Yoseph H; Hussein K; Braun E; Paul M
    J Antimicrob Chemother; 2016 Oct; 71(10):2729-39. PubMed ID: 27317444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subsequent infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with prior infection or fecal colonization.
    Lindblom A; Karami N; Magnusson T; Åhrén C
    Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1491-1497. PubMed ID: 29796984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae is common 12 months after infection and is related to strain factors.
    Titelman E; Hasan CM; Iversen A; Nauclér P; Kais M; Kalin M; Giske CG
    Clin Microbiol Infect; 2014 Aug; 20(8):O508-15. PubMed ID: 24450760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal Dynamics and Risk Factors for Bloodstream Infection With Extended-spectrum β-Lactamase-producing Bacteria in Previously-colonized Individuals: National Population-based Cohort Study.
    Isendahl J; Giske CG; Hammar U; Sparen P; Tegmark Wisell K; Ternhag A; Nauclér P
    Clin Infect Dis; 2019 Feb; 68(4):641-649. PubMed ID: 29961883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for the eradication of extended-spectrum beta-lactamase or carbapenemase-producing Enterobacteriaceae intestinal carriage.
    Catho G; Huttner BD
    Expert Rev Anti Infect Ther; 2019 Aug; 17(8):557-569. PubMed ID: 31313610
    [No Abstract]   [Full Text] [Related]  

  • 12. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial.
    Huttner BD; de Lastours V; Wassenberg M; Maharshak N; Mauris A; Galperine T; Zanichelli V; Kapel N; Bellanger A; Olearo F; Duval X; Armand-Lefevre L; Carmeli Y; Bonten M; Fantin B; Harbarth S;
    Clin Microbiol Infect; 2019 Jul; 25(7):830-838. PubMed ID: 30616014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do probiotics prevent colonization with multi-resistant Enterobacteriaceae during travel? A randomized controlled trial.
    Dall LB; Lausch KR; Gedebjerg A; Fuursted K; Storgaard M; Larsen CS
    Travel Med Infect Dis; 2019; 27():81-86. PubMed ID: 30508633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for community-onset bloodstream infection with extended-spectrum β-lactamase-producing Enterobacteriaceae: national population-based case-control study.
    Isendahl J; Giske CG; Tegmark Wisell K; Ternhag A; Nauclér P
    Clin Microbiol Infect; 2019 Nov; 25(11):1408-1414. PubMed ID: 30986557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of probiotics to reduce infections and death and prevent colonization with extended-spectrum beta-lactamase (ESBL)-producing bacteria among newborn infants in Tanzania (ProRIDE Trial): study protocol for a randomized controlled clinical trial.
    Kuwelker K; Langeland N; Löhr IH; Gidion J; Manyahi J; Moyo SJ; Blomberg B; Klingenberg C
    Trials; 2021 Apr; 22(1):312. PubMed ID: 33926519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low rate of gut colonization by extended-spectrum β-lactamase producing Enterobacteriaceae in HIV infected persons as compared to healthy individuals in Nepal.
    Hosuru Subramanya S; Bairy I; Nayak N; Padukone S; Sathian B; Gokhale S
    PLoS One; 2019; 14(2):e0212042. PubMed ID: 30779752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relating knowledge, attitude and practice of antibiotic use to extended-spectrum beta-lactamase-producing Enterobacteriaceae carriage: results of a cross-sectional community survey.
    Mo Y; Seah I; Lye PSP; Kee XLJ; Wong KYM; Ko KKK; Ong RT; Tambyah PA; Cook AR
    BMJ Open; 2019 Mar; 9(3):e023859. PubMed ID: 30842108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
    Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
    BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decolonization strategies for ESBL-producing or carbapenem-resistant Enterobacterales carriage: a systematic review and meta-analysis.
    Zhang HJ; Wang HW; Tian FY; Yang CZ; Zhao M; Ding YX; Wang XY; Cui XY
    Sci Rep; 2024 Oct; 14(1):24349. PubMed ID: 39420082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of Resistance Plasmids in Extended-Spectrum-β-Lactamase-Producing
    Brolund A; Rajer F; Giske CG; Melefors Ö; Titelman E; Sandegren L
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.